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ABSTRACT
Chloride intracellular channel 1 (CLIC1) is highly expressed and secreted by 
human glioblastoma cells and cell lines such as U87, initiating cell migration and tumor 
growth. Here, we examined whether CLIC1 could be transferred to human primary 
microvascular endothelial cells (HMEC). We previously reported that the oncogenic 
microRNA, miR-5096, increased the release of extracellular vesicles (EVs) by which 
it increased its own transfer from U87 to surrounding cells. Thus, we also examined 
its effect on the CLIC1 transfer. In homotypic cultures, miR-5096 did not increase 
the expression of CLIC1 in U87 nor in HMEC. However, the endothelial CLIC1 level 
increased after exposure to EVs released by U87, and even more by miR-5096-loaded 
U87. The EVs-transferred CLIC1 was active in HMEC, promoting endothelial sprouting 
in matrigel. Cell exposure to EVs induced cytosolic Ca2+ spikes which were dependent 
on the transient receptor potential melastatin member 7 (TRPM7). TRPM7 silencing 
prevented Ca2+ spikes and the subsequent CLIC1 delivery into HMEC. Our data suggest 
that the vesicular transfer of CLIC1 between cells requires TRMP7 expression in 
recipient endothelial cells. How the vesicular transfer of CLIC1 is modulated in cancer 
therapy is a future challenge.
INTRODUCTION
Extracellular vesicles (EVs) are membrane-
enclosed particles released from either endosomes or 
the cell surface [1–3]. EVs are composed of an array of 
proteins, nucleic acids, lipids, and other metabolites that 
reflect the cell of origin. They offer an intercellular route 
to transfer oncogenic material that change the functions 
of non-malignant cells, i.e. proliferation, invasion, and 
angiogenesis [2]. Their secretion is correlated to the 
cell’s ability to produce invadopodia (actin-rich cellular 
protrusions with proteolytic activity); i.e., inhibition of 
invadopodia formation decreased exosome release [3–5]. 
Importantly, glioblastoma (GBM)-derived EVs can cross 
the brain–blood-barrier and are detectable in the systemic 
blood circulation [6]. Profiling the composition of GBM-
derived EVs may, therefore, offer a non-invasive means of 
assessing tumors in situ [4].
Studies have described extensive RNA expression 
analyses of GBM-derived EVs, however, proteomic 
profiles are currently limited [4, 7]. Among the vesicular 
proteins, one study identify the chloride intracellular 
channels (CLIC) carried by exosomes between GBM 
cells [8]. The CLIC family form a class of proteins that 
do not fit the paradigm set by classical ion channels 
(for review see; [9–11]). They can exist as both soluble 
globular proteins and integral membrane proteins with 
ion channel function. The first member of CLIC, namely 
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CLIC1 (also known as NCC27), holds pathological 
implications in a variety of tumors, being involved in cell 
proliferation, motility, and angiogenesis [12–15]. CLIC1 
is overexpressed in glioblastoma (GBM), with highest 
expression in patients with poor prognosis [13]. CLIC1 
is also secreted in extracellular vesicles (EVs) by cancer 
cells [8] and is detected in biological fluids [8, 16, 17], 
fostering the hypothesis that secreted CLIC1 protein may 
increase GBM growth. Interestingly, Setti et al [8] have 
shown that the secretion of CLIC1 via EVs is common 
to all human GBM cell lines (U87MG, A172, LN405, 
U118MG, T98G, DBTRG-05MG and U373 MG). If the 
number of secreted EVs differs from one type of lineage to 
another, the membrane markers and biophysical properties 
of EVs are similar.
Using U87 GBM cell line, we have recently 
described that miR-5096 increases the outgrowth of 
filopodia in glioma cells, and promotes the extracellular 
release of EVs by U87 thereby promoting its own transfer 
to surrounding cells [18]. Here, we show that EVs also 
contain active CLIC1 whose amount is not significantly 
increased by miR-5096. The transfer of CLIC1 to human 
microvascular endothelial cells (HMEC) requires Ca2+ 
spikes and TRPM7 for their uptake, and contributes to 
endothelial sprouting [19, 20].
RESULTS
Extracellular vesicles from GBM cells transfer 
active CLIC1 to HMEC
Both U87 and HMEC expressed CLIC1 proteins, as 
already reported [12, 21]. Immunoblot analysis of whole 
cell lysates (WCL) from homotypic cultures revealed that 
the cell loading with miR-5096 mimic or inhibitor did not 
significantly change CLIC1 expression after 48h in both 
U87 and HMEC (Figure 1A). This is in agreement with the 
absence of miR-5096 effect on CLIC1 mRNA expression 
(not shown) and predictions from bioinformatics tools 
which failed to identify any target site for miR-5096 in 
CLIC1 gene and mRNA. However, the endothelial CLIC1 
level was increased after 24h-exposure of HMEC to U87-
conditioned media (Figure 1B). We next separated EVs 
from the effluent (soluble fraction) of culture media as 
described previously [18]. In all cases, EVs and effluents 
were adjusted to the same number of U87 (i.e. 4 x 106 
cells), then applied to homotypic HMEC cultures for 24h. 
Cell exposure to EVs released from miR-5096-loaded U87 
significantly increased CLIC1 levels in HMEC, while the 
effluent (EVs-free) did not (Figure 1B). The immunoblot 
analysis of EVs showed an enrichment in the exosome 
specific protein tsg101 (tumor susceptibility gene 101) [8, 
18] (Figure 1C). Clearly, EVs contained CLIC1 proteins 
and their level seemed to be higher in EVs from miR-
loaded U87 than from empty-loaded U87. A possible 
explanation might be that miR5096 induced an increase 
in EVs release [18], rather than a significant increase 
in CLIC1 vesicular content. To confirm the transfer of 
CLIC1 to HMEC, endogenous CLIC1 was silenced by 
using siRNA in a series of experiments (i.e. relative OD 
of 0.406±0.061 and 0.015±0.007, respectively before and 
after CLIC1 silencing; P<0.05, n=3). As shown in Figure 
1C, both cellular (WCL) and vesicular (EVs lysates) 
CLIC1 contents were suppressed in HMEC by CLIC1 
siRNA. The CLIC1 immuno-labelling showed that 
CLIC1 was mostly found in perinuclear areas of control 
HMEC (Figure 1D). No labelling was observed after 
silencing CLIC1 in HMEC. After 24h of cell incubations 
with EVs from miR-5096 loaded U87, we detected 
CLIC1 in both the cytosol and the plasma membrane of 
control and silenced HMEC. We also overexpressed a 
fluorescent-tagged version of human CLIC1 in U87 and 
collected conditioned media after 48h (see Supplementary 
Figure 2). Exposure of HMEC to isolated EVs resulted 
to the fluorescent labelling of HMEC after 24h. Thus, 
the increase of CLIC1 in HMEC resulted more from a 
vesicular transfer of CLIC1 rather than an up-regulation 
of its endogenous expression in recipient HMEC. Are 
the transferred proteins active in the recipient cells? 
Using a 24-hour three-dimensional in vitro angiogenesis 
assay, we explored the ability of vesicular CLIC1 to 
induce endothelial spheroid sprouting [22]. As shown in 
Figure 1E, EVs stimulated HMEC sprouting even more 
when collected from miR-loaded U87 (M) (see also 
Supplementary Figure 1A). This effect was partially 
prevented by silencing CLIC1 in U87 (Msi). To confirm 
the contribution of vesicular CLIC1 to angiogenesis, EVs 
were also tested on branching morphogenesis in vitro [22]. 
HMEC control and CLIC1 silenced were plated in ECM 
gel and exposed or not (Co) to EVs collected from the 
same number of U87. Quantification of average number 
of processes per cell was performed after 12h (Figure 
1F; see also Supplementary Figure 1B). Silencing CLIC1 
in HMEC decreased the branching as expected for its 
contribution to in vitro angiogenesis [12]. Exposure to 
EVs stimulated the branching even more when collected 
from miR-5096-loaded U87 (M). This effect was partially 
prevented by silencing CLIC1 in secretory U87 (Msi). 
Thus, the vesicular CLIC1 was active in recipient HMEC 
and contributed to early steps of in vitro angiogenesis [12].
EVs-mediated CLIC1 transfer to HMEC 
requires TRPM7-dependent Ca2+ signaling
In order for EVs to elicit a signaling response from 
recipient cells, they can fuse with plasma membrane or 
are taken up via endocytosis or attach to the cell surface 
[23] (see Supplementary Figure 2). Since endocytosis, 
receptor internalization and trafficking are regulated by 
cytosolic Ca2+ level [24, 25], we determined whether the 
endothelial uptake of vesicular CLIC1 was associated 
with cytosolic Ca2+ fluctuations. Spatio-temporal Ca2+ 
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Figure 1: Active CLIC1 protein is transferred via vesicles from GBM to endothelial cells. Immunoblot analysis of CLIC1 in 
whole cell lysates (WCL) from homotypic cultures of U87 and HMEC, 48 h after loading. Untreated cells were used as control (Co). Cells 
were loaded empty (E) or with 30nM miR5096 mimic (M) or inhibitor (I). β-actin as loading control (60μg proteins/lane). Numbers indicate 
mean values of optical densities (OD) of CLIC1 relative to β–actin (± SD; P>0.05 vs Co; n = 3). (B) CLIC1 increased in HMEC after 
24 h of incubation with EVs. Cell-conditioned media were collected from homotypic U87 miR-loaded (M) or not (E), 48h after loading. 
HMEC were exposed to EVs or effluent (soluble fraction) separated from U87-conditioned media. Numbers indicate mean OD values of 
CLIC1 relative to β-actin (± SD; *P<0.05 vs Co; n = 3). (C) EVs contained CLIC1. Lysates of EVs were immunoblotted for the marker 
tsg101. Homotypic U87 were loaded (M) or not (E) upon transfection of control siRNA or siRNA targeting CLIC1. Silencing CLIC1 was 
also tested in HMEC (WCL) and HMEC-released EVs (Hsc70 as loading control). Numbers indicate mean OD values of CLIC1 related 
to tsg101 for EVs lysates (± SD; *P<0.05 vs Co (E); n = 4). (D) Endothelial cell localization of CLIC1. HMEC were silenced by siRNA 
CLIC1 then exposed to EVs collected from homotypic U87 (M) (n = 3). CLIC1 stained with alexa Fluor 594 (red) and nuclear DNA with 
Dapi (blue). (E) CLIC1 effect on the length of endothelial sprouts formed from spheroïds in Matrigel for 24h, in the absence (Co) or the 
presence of EVs collected from homotypic U87 empty (E) or miR5096-loaded (M). When indicated by Msi, CLIC1 was silenced by siRNA 
in U87 (M). Data are means ± SD (*P-values<0.05 vs control; n=10) in two independent experiments. (F) Contribution of CLIC1 to the 
branching morphogenesis in HMEC cultured in collagen ECM gel for 12 h, in the absence (Co) or presence of EVs. Histogram shows the 
average number of processes per cell. Control and CLIC1 siRNA HMEC are filled black and yellow, respectively. Data are means ± SD 
(*P<0.05, **P<0.01 vs Co; n=10) in two experiments. (G) EVs induced Ca2+ spikes in HMEC. Representative line scan images of cytosolic 
[Ca2+] in Fluo-4-loaded HMEC exposed to the standard solution, to EGF (10 ng/ml) and to EVs (from U87) as indicated by arrows. Space 
and time ordinates are displayed in the horizontal and vertical directions, respectively (scan rate 22.3 μsec/line). Amplitudes of Ca2+ signal 
are expressed as the fluorescent rapport F/F0 (pseudo-colors) in a tridimensional histogram (F/F0 vs space/time). In all cases, the line scan 
crossed both cytosol and nuclei of 4 adjacent cells, as shown in the 1024x1024 pixel panel. Note that Ca2+ spikes were observed at the 
beginning of all recordings (due to the initial cell perfusion) and were not reproduced by reapplying the standard solution.
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variations were recorded in HMEC loaded with Fluo-4 
by using line scanning of confocal microscopy [26]. No 
Ca2+ spike was observed in standard external conditions 
(Figure 1G; upper panel). As a positive control, HMEC 
were exposed to epidermal growth factor (EGF), inducing 
a typical pattern of Ca2+ signal [27], i.e. a rapid increase 
in cytosolic Ca2+ which was maintained several minutes 
before decaying to the resting level, followed by a 
second transient increase observed about 6 min later. 
The endothelial cell exposure to EVs from U87 elicited 
a similar Ca2+ signal although with a lower amplitude 
than did EGF (i.e. max F/F0 of 1000 ± 500 with EVs 
and 3000±600 with EGF; P<0.05, n=6). Of note, the lag 
time between successive Ca2+ waves was similar (6.61 
± 1.25 min; P>0.05; n=6). The well-known inhibitor 
of Ca2+ pathways, 2-APB [28–31], suppressed EVs-
evoked Ca2+ signal (Figure 2A, lower panel) as well as 
the subsequently CLIC1 delivery to HMEC (Figure 2B). 
Indeed, incubations of 2-APB-treated HMEC with EVs 
for 24 h did not increase CLIC1 labelling, especially in 
CLIC1-silenced HMEC (Figure 2B). Among 2-APB-
sensitive channels in plasma membranes, the melastatin-
subfamily of TRP (TRPM7) is a non-specific divalent 
cation channel upregulated in GBM [29]. To estimate 
its contribution in both Ca2+ waves and CLIC1 delivery 
to HMEC, endogenous TRPM7 was silenced by using 
siRNA (Figure 2C, 2D). Cell exposure to EVs already 
produced cytosolic Ca2+ waves which were decreased by 
silencing TRPM7 (Figure 2E). Unfortunately, we could 
not knockdown both TRPM7 and CLIC1 since HMEC 
did not survive. After 24h of cell incubations with EVs, 
CLIC1 labeling was also decreased in cytosol or plasma 
membrane of TRPM7-silenced HMEC, attesting the 
partial contribution of TRPM7 in this process (Figure 
2F). Of note, cell exposure to soluble fractions (EVs-free 
effluent) from U87-conditioned media did not increase 
TRPM7 levels in HMEC, while the miR5096 loading or 
Kir4.1 silencing did (Figure 2C, 2G). Thus, the vesicular 
transfer of CLIC1 to HMEC required Ca2+ signaling 
mediated, at least in part, by TRPM7.
DISCUSSION
We report here that CLIC1 protein is transferred 
via EVs from the GBM cell line U87 to microvascular 
endothelial cells where it remains active, i.e. induces 
endothelial sprouting. When applied onto HMEC, EVs 
elicit Ca2+ “spikes” which can be prevented by 2-APB. 
Although 2-APB inhibits numerous channels including 
IP3 receptors [28], store-operated Ca
2+ channels [30] and 
TRP channels [29, 31], silencing TRPM7 prevents Ca2+ 
spikes and the subsequent CLIC1 uptake by HMEC. 
Altogether, our data show that CLIC1 secreted by cancer 
cells via extracellular vesicles, modulates the activity 
of neighboring endothelial cells in a TRPM7 dependent 
manner, promoting tumor angiogenesis.
We previously reported that miR-5096 favors its 
own transfer from U87 to HMEC via an increased release 
of EVs, two days after its loading in U87 [18]. Here, we 
show that EVs also contain CLIC1 and mostly ensure 
its transfer to HMEC (Figure 1; see also Supplementary 
Figure 2). EVs are composed of an array of proteins, 
nucleic acids, lipids, and other metabolites that reflect the 
cell of origin [4]. We report that EVs, secreted by the same 
number of U87, produce a greater increase in active CLIC1 
in the recipient HMEC when the donor U87 are previously 
loaded with miR-5096. The most likely explanation is 
that miR-5096 induces an increase in EVs release [18], 
rather than a significant increase in CLIC1 vesicular 
content. How miR-5096 exerts such an effect is currently 
unknown and not explored in our study. Nevertheless, 
evidence increasingly points to a connection between lipid 
metabolism and cancer, characterized by an alteration in 
the mechanisms that regulate cholesterol homeostasis [32]. 
It is known that the survival of GBM cells is dependent 
on uptake of cholesterol [33] in which some microRNAs 
are the fine tuners [34, 35]. Interestingly, cholesterol 
promotes the conversion of CLIC1 from cytosolic to 
transmembrane proteins [36], thus facilitates its docking 
to the membranes [37, 38]. Drawing on the data above, 
we propose a pure speculative model where miR-5096 
increases cholesterol and CLIC1 is involved in recruiting 
EVs, leading to an increased secretion of EVs by U87 cells 
(see Supplementary Figure 3).
By overexpressing fluorescent-tagged CLIC1 
proteins (CLIC-OFP) in U87, we observe CLIC1-OFP 
inside the invadopodia (see Supplementary Figure 2B). 
Upon exposure to EVs, HMEC become fluorescent and 
change their morphology; i.e. showing invadopodia 
formation. Invadopodia act as multivesicular endosome 
docking sites and are a site of EVs release, meaning 
the cell’s ability to form invadopodia determines their 
ability to release of EVs [4, 5]. In this process, CLIC1 
would contribute to the formation of invadopodia in 
endothelial and tumor cells, by inducing integrin-mediated 
actomyosin dynamic [15]. Changes in CLIC1 location 
from cytosolic to transmembrane proteins are associated 
with malignant transformation [15]. Our study does not 
allow to distinguish the two forms of CLIC1 (i.e. soluble 
form and membrane-inserted chloride conducting pore). 
However, immuno-labeling of CLIC1 confirms its 
previously described nuclear location in steady HMEC 
[9]. Following exposure to EVs, CLIC1 is also detected 
in cytosol and weakly at the plasma membrane of HMEC 
within 24h. On the other hand, the endothelial sprouting 
in matrigel is increased by EVs within 24h. This effect 
is partially prevented by silencing CLIC1 in donor U87 
and is not attributed to miR-5096 itself [39]. Our results 
are in agreement with the literature showing that a low 
CLIC1 expression in endothelium decreases capillary-like 
sprouting in matrigel [12, 14, 15]. We observe a functional 
difference between silencing all CLIC1 and preventing 
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Figure 2: The vesicular transfer of CLIC1 requires cytosolic Ca2+ increases in HMEC. (A) Line scan images of cytosolic 
[Ca2+] increases in Fluo-4 loaded HMEC exposed to the same amount of EVs collected from the same homotypic U87 culture. HMEC 
were pre-treated with 2-APB (50 μM; lower panel). Tridimensional histogram (F/F0 vs space/time) are representative of 3 experiments. 
(B) Transfer of vesicular CLIC1 was blocked by 2-APB (50 μM). HMEC silenced by siRNA CLIC1 were exposed to EVs from U87 (n 
= 3). After 24h of incubation with EVs, HMEC were stained for CLIC1 (red) and nuclei (blue). (C) Expression of TRPM7 in HMEC. 
Homotypic HMEC were loaded (M) or not (E) with miR-5096 upon transfection of control siRNA or siRNA targeting TRPM7. Numbers 
indicate mean OD values of TRPM7 related to β-actin (± SD; n = 2; 80μg proteins/lane). (D) Spatially average Ca2+ profile showing the 
dynamic change of Ca2+ signals with time and induced by EVs (applied at the beginning of the records) then EGF (10 ng/ml) applied at the 
time indicated by arrow. Cytosolic Ca2+ store depletion was performed by the addition of thapsigargin (TSG, 5μM) at the end of recordings. 
Values are means of fluorescent ratio F/F0 ± SD; n = 3. (E) Silencing TRPM7 in HMEC reduced the Ca2+ signal induced by EVs collected 
from homotypic U87 for 48h. (F) Control and silenced TRPM7 HMEC were exposed to EVs and stained for CLIC1 (red) after 24 h of 
culture (representative of 3 experiments). (G) Expression of TRPM7 in homotypic HMEC upon transfection of control siRNA or siRNA 
targeting Kir4.1 [18]. HMEC were exposed to the effluent (soluble fraction) from homotypic U87. Numbers indicate mean OD values of 
TRPM7 related to β-actin (± SD; n = 2).
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only the U87-derived CLIC1 delivery. This cannot be 
easily explained since EVs probably contain proangiogenic 
factors, miRNAs and extracellular proteases which are 
required by endothelial cells to proliferate, migrate, 
and organize into new tubular structures [4, 40]. For 
instance, EVs from xenografts of glioblastomas contain an 
oncogenic variant of the epidermal growth factor receptor 
(EGFRvIII), which can be transferred to endothelial 
cells, producing proliferation and tubulogenesis [41, 42]. 
A broad array of cell surface and signaling proteins is 
involved in tubulogenesis [43], and could explain why 
the perivascular invasion is more important in vascular 
endothelial growth factor (VEGF)-deficient glioblastoma 
cells and brain tumor xenografts treated with anti-VEGF 
blocking antibodies such as bevacizumab [44, 45].
We hypothesize that EVs bind to recipient 
endothelial cells (see Supplementary Figure 4). These 
EVs may remain at the plasma membrane [46] or may be 
internalized by endocytosis either mediated by clathrin 
[47, 48] or via caveolae and lipid rafts [49]. These 
mechanisms require Ca2+ increase at the submembrane 
level [50, 51]. While the precise mechanism of CLIC1 
uptake and processing in HMEC remains unclear, we 
show for the first time that CLIC1 transfer requires 
an initial Ca2+ signaling in recipient cells within 1h. 
Moreover, the EVs-induced Ca2+ signal is suppressed 
in nominally Ca2+-free standard solution (i.e. no CaCl2 
added; data not shown), attesting the involvement of 
an external Ca2+ entry. Among the putative Ca2+ entry 
pathways, the presence of functional TRPM7 channels 
is known in human endothelial cells [52–55]. By using 
specific siRNA, we identify TRPM7 as a mediator for 
this Ca2+ entry needed for CLIC1 uptake by HMEC. Of 
note, TRPM7 contributes to the EGF-induced Ca2+ signal, 
without affecting the Ca2+ content of internal Ca2+ stores 
sensitive to thapsigargin (see Supplementary Figure 1C).
High CLIC1 expression is involved in the 
progression of GBM and other tumors [56–58] and 
correlates with a poor patient outcome [13]. Our data 
foster the hypothesis that CLIC1 transfer to endothelial 
cells via EVs contributes to GBM growth by promoting 
capillary formation [12, 14, 15, 56]. Moreover, the 
pharmacological inhibition or silencing of TRPM7 
inhibits adhesion or invasion in cancer cell lines [19, 
59–61] as well as migration of HMEC [53]. Of note, 
TRPM7 expression is increased in miR-5096 loaded U87 
(see Supplementary Figure 1D). Because the silencing 
of potassium Kir4.1 channels [18] also produces this 
increase, this up-regulation of TRPM7 should result more 
from a membrane potential variation than from a direct 
effect of miR-5096 on TRPM7 gene or mRNA [62]. 
Nevertheless, it is still not clear whether other proteins 
and miRNAs could be transferred via EVs to modulate 
channels in recipient cells [63, 64]. Further investigations 
are required to fully resolve the functional capabilities of 
EVs [65–67].
MATERIALS AND METHODS
Cells
Human primary microvascular HMEC (HMVEC-D; 
Lonza) and U87-MG cells (ATCC HTB-14) were grown 
in DMEM plus 10% FCS (5% CO2; 37°C). Cells were 
incubated 48 h in FCS-free media before use.
Reagents
Monoclonal anti-Tsg101, anti-Hsc70 and anti-
β-actin were purchased from Santa Cruz Biotech 
(Clinisciences, Fr). Monoclonal anti-CLIC1 (ab77214) 
and anti-TRPM7 (ab109438) were from Abcam. 
Fluo-4 acetomethyl (AM) ester was from Invitrogen 
(ThermoFisher). 2-Aminoethyl diphenylborinate (2-APB), 
thapsigargin (TSG) and other chemicals were from Sigma-
Aldrich.
Transfection
Cells were transfected by lipofectamine 
RNAiMAX according to the manufacturer’s protocol 
(Invitrogen). Human hsa-miR-5096 mimic (mirVana TM 
miRNA, 4464066-MC22429) and inhibitor (4464084-
MH22429) were purchased from Ambion (Invitrogen; 
ThermoFisher) [18]. Human TRPM7 siRNA (ID 1490) 
and CLIC1 siRNA (ID 145733) were purchased from 
(Ambion, AM51331). The sequences were: siRNA 
CLIC1 (5’-GAGCUUGUGUUGUGCUGAAtt-3’ and 
5’-UUCAGCACAACACAAGCUCtt-3’); siRNA TRPM7 
(5’-GGACCCUCACAGAUGCCUUtt-3’ and 5’-AAGG 
CAUCUGUGAGGGUCCtt-3’). To downregulate Kir4.1, 
cells were transfected with human KCNJ10 siRNA 
SMARTpool (30 nM) purchased from Dharmacon 
(ThermoFisher), as we described previously [18]. To 
overexpress fluorescent CLIC1 proteins, we transfected 
U87 cells with the human CLIC1/NCC27 gene ORF 
cDNA clone expression plasmid, C-OFPSpark (HG15242-
ACR, Sino Biological Inc.; purchased from Interchim, 
Montluçon, Fr). Cells were used after 48h.
Immunoblotting
Cells were lysed in RIPA buffer, and Western blots 
were performed as previously described [18]. EVs pellets 
were lysed in RIPA buffer containing protease inhibitor 
cocktail (Roche, Indianapolis, IN) then sonicated for 10 
s. Insoluble material was pelleted by centrifugation for 15 
min at 14,000 g at 4°C.
Immunofluorescence
Cells were fixed in 4% PFA and permeabilized with 
0.1% Triton X-100. Images were performed using a Leica 
SP2 RS confocal microscope (Z-series of 0.6 μm-optical 
sections; 512x512 pixels).
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EVs isolation
After 48h of culture in FCS-free conditions, cell-
conditioned media were collected and sequentially 
centrifuged at 300 g for 10 min (4°C) then at 2,000 
g for 10 min to remove cell debris [18, 68]. EVs were 
collected by ultracentrifugation at 100,000 g for 90 min. 
Concentrations were adjusted to the same number of cells 
(i.e. corresponding to the secretion from 4 x 106 cells).
Cell sprouting assay in collagen gels
Sprouting of HMEC spheroids was performed 
as previously described [69]. For each gel, 8 spheroids 
(each containing 400 – 500 cells) were seeded into 0.7 
ml collagen solution in 24-well plates (PromoCell GmbH) 
and incubated with the tested solutions for 24h (5% 
CO2; 37°C). The cumulative sprout length of 8 randomly 
selected spheroids was measured for each tested group.
Endothelial tube formation assay in collagen gels
Control and silenced CLIC1 HMEC were plated 
in DMEM ECM gel, with or without EVs collected from 
U87, according to the manufacturer’s instructions (from 
Cell Biolabs, Inc). After 12 hours of incubation at 37°C, 
80 single cells were scored for the number of processes 
per cell. Each well is duplicated for each experiment, and 
each experiment was repeated three times.
Calcium imaging
Spatiotemporal Ca2+ variations were recorded in 
HMEC cultured on uncoated glass then loaded with 4μM 
Fluo4/AM in FCS-free conditions for 40 min at 37°C [26]. 
Cells were bathed in the standard solution containing (in 
mM): 136 NaCl, 5 KCl, 1 MgCl2, 1.8 CaCl2, 0.3 NaH2PO4, 
10 Glucose, and 10 HEPES (pH 7.4). Measurements were 
performed by a line scan crossing 3-4 cells in a 1024x1024 
pixel panel using a confocal microscope (Nikon C1Si) 
with 100x objective (Nikon, Melville, NY). Excitation was 
at 488 nm and emission-selected at 500-570 nm. Line scan 
images in pseudo-colors were acquired at a sampling rate 
of 22.3 μsec per line (32 lines/sec). To compare cytosolic 
[Ca2+] fluctuations, fluorescent measurements (F) were 
expressed as the F/F0 ratio, where F0 refers to the basal 
[Ca2+] fluorescence at rest [70]. The signal amplitudes 
were shown in a tridimensional histogram (F/F0 as a 
function of time/length).
Statistical analysis
Results are expressed as mean ± SD. A Mann-
Whitney U test was used to compare data groups. Statistics 
were also made with Tanagra software using a Kruskal-
Wallis 1-way ANOVA. In all cases, *P values < 0.05 were 
significant.
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